187 related articles for article (PubMed ID: 21598243)
1. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA
Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243
[TBL] [Abstract][Full Text] [Related]
2. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
3. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone for the treatment of breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
8. Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Sherrill B; Sherif B; Amonkar MM; Maltzman J; O'Rourke L; Johnston S
Curr Med Res Opin; 2011 Dec; 27(12):2245-52. PubMed ID: 21992075
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
10. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Fornier M
Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES
J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
[No Abstract] [Full Text] [Related]
12. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Vrdoljak E; Mise BP; Lukić B; Curić Z; Bosković L; Tica I
Onkologie; 2010; 33(1-2):53-6. PubMed ID: 20164663
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Sherrill B; Di Leo A; Amonkar MM; Wu Y; Zvirbule Z; Aziz Z; Bines J; Gomez HL
Curr Med Res Opin; 2010 Apr; 26(4):767-75. PubMed ID: 20095796
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone, a new treatment option for metastatic breast cancer.
Toppmeyer DL; Goodin S
Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Zhou X; Cella D; Cameron D; Amonkar MM; Segreti A; Stein S; Walker M; Geyer CE
Breast Cancer Res Treat; 2009 Oct; 117(3):577-89. PubMed ID: 19153829
[TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Reed SD; Li Y; Anstrom KJ; Schulman KA
J Clin Oncol; 2009 May; 27(13):2185-91. PubMed ID: 19332722
[TBL] [Abstract][Full Text] [Related]
19. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Sherrill B; Amonkar MM; Stein S; Walker M; Geyer C; Cameron D
Br J Cancer; 2008 Sep; 99(5):711-5. PubMed ID: 18728660
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
